TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer
- Carey, Lisa A.
- Rugo, Hope S.
- Marcom, P. Kelly
- Mayer, Erica L.
- Esteva, Francisco J.
- Ma, Cynthia X.
- Liu, Minetta C.
- Storniolo, Anna Maria
- Rimawi, Mothaffar F.
- Forero-Torres, Andres
- Wolff, Antonio C.
- Hobday, Timothy J.
- Ivanova, Anastasia
- Chiu, Wing-Keung
- Ferraro, Madlyn
- Burrows, Emily
- Bernard, Philip S.
- Hoadley, Katherine A.
- Perou, Charles M.
- Winer, Eric P.
Publication date
January 2012
DOIAbstract
Epidermal growth factor receptor (EGFR) is a targetable receptor frequently overexpressed in basal-like breast cancer, which comprises most triple-negative breast cancers (TNBCs), the only subtype without established targeted therapy
Add to ORKG